Victor R Gordeuk

List of Publications by Year in Descending Order

221 papers	5,362 citations	38 h-index	70 g-index
227 ext. papers	6,554 ext. citations	5.3 avg, IF	5.35 L-index

#	Paper	IF	Citations
221	Voxelotor and albuminuria in adults with sickle cell anaemia.. *British Journal of Haematology*, **2022**,	4.5	0
220	An evaluation of patient-reported outcomes in sickle cell disease within a conceptual model.. *Quality of Life Research*, **2022**, 1	3.7	
219	Antimicrobial resistance is a risk factor for mortality in adults with sickle cell disease. *Haematologica*, **2021**, 106, 1745-1748	6.6	1
218	Biomarker Association with Hypertension in Mild Versus Severe Sickle Cell Disease Genotypes of a Single Center Cohort, in Comparison with African Americans from the Nhanes Study. *Blood*, **2021**, 138, 2051-2051	2.2	
217	HIF-Mediated and Non-HIF-Mediated Differential Gene Expressions in Sickle Cell Reticulocyte and Their Impact on Clinical Manifestations. *Blood*, **2021**, 138, 950-950	2.2	
216	Constitutive Expression of Hypoxia Inducible Factor Downregulates the Anticoagulant Protein S in a Unique Chuvash Polycythemia Population with Erythrocytosis. *Blood*, **2021**, 138, 4259-4259	2.2	
215	Targeted Proteomics of Pulmonary Hypertension in Sickle Cell Disease. *Blood*, **2021**, 138, 981-981	2.2	
214	Exercise-induced changes of vital signs in adults with sickle cell disease. *American Journal of Hematology*, **2021**, 96, 1630-1638	7.1	0
213	Comparing the Effectiveness of Education Versus Digital Cognitive Behavioral Therapy for Adults With Sickle Cell Disease: Protocol for the Cognitive Behavioral Therapy and Real-time Pain Management Intervention for Sickle Cell via Mobile Applications (CaRISMA) Study. *JMIR Research Protocols*, **2021**, 10, e29014	2	5
212	Evaluation of point-of-care International Normalized Ratio in sickle cell disease. *Research and Practice in Thrombosis and Haemostasis*, **2021**, 5, e12533	5.1	
211	Time to rethink haemoglobin threshold guidelines in sickle cell disease. *British Journal of Haematology*, **2021**, 195, 518-522	4.5	1
210	Biomarkers of clinical severity in treated and untreated sickle cell disease: a comparison by genotypes of a single center cohort and African Americans in the NHANES study. *British Journal of Haematology*, **2021**, 194, 767-778	4.5	1
209	Multiple-ancestry genome-wide association study identifies 27 loci associated with measures of hemolysis following blood storage. *Journal of Clinical Investigation*, **2021**, 131,	15.9	8
208	Engulfment and cell motility 1 (ELMO1) and apolipoprotein A1 (APOA1) as candidate genes for sickle cell nephropathy. *British Journal of Haematology*, **2021**, 193, 628-632	4.5	3
207	Identifying adolescent and young adult patients with sickle cell disease at highest risk of death. *American Journal of Hematology*, **2021**, 96, 9-11	7.1	2
206	Urinary Kringle Domain-Containing Protein HGFL: A Validated Biomarker of Early Sickle Cell Anemia-Associated Kidney Disease. *American Journal of Nephrology*, **2021**, 52, 582-587	4.6	0
205	Effects of Renin-Angiotensin Blockade and on Kidney Function in Sickle Cell Disease. *EJHaem*, **2021**, 2, 483-484	0.9	1

204	Patient-reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease. *American Journal of Hematology*, **2021**, 96, 1396-1406	7.1	7
203	Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection. *Blood Advances*, **2021**, 5, 207-215	7.8	25
202	Thrombomodulin and multiorgan failure in sickle cell anemia.. *American Journal of Hematology*, **2021**,	7.1	
201	Development of a Severity Classification System for Sickle Cell Disease. *ClinicoEconomics and Outcomes Research*, **2020**, 12, 625-633	1.7	5
200	Clinical, laboratory, and genetic risk factors for thrombosis in sickle cell disease. *Blood Advances*, **2020**, 4, 1978-1986	7.8	8
199	Peripheral blood mononuclear cells show prominent gene expression by erythroid progenitors in diseases characterized by heightened erythropoiesis. *British Journal of Haematology*, **2020**, 190, e42-e45	4.5	
198	Sickle cell vaso-occlusion: the clot thickens. *Blood*, **2020**, 135, 1726-1727	2.2	
197	Thrombotic risk in congenital erythrocytosis due to up-regulated hypoxia sensing is not associated with elevated hematocrit. *Haematologica*, **2020**, 105, e87-e90	6.6	6
196	Patient-reported outcomes in sickle cell disease and association with clinical and psychosocial factors: Report from the sickle cell disease implementation consortium. *American Journal of Hematology*, **2020**, 95, 1066-1074	7.1	11
195	Increased iron stores influence glucose metabolism in sickle cell anaemia. *British Journal of Haematology*, **2020**, 189, e184-e187	4.5	0
194	Publication of data collection forms from NHLBI funded sickle cell disease implementation consortium (SCDIC) registry. *Orphanet Journal of Rare Diseases*, **2020**, 15, 178	4.2	8
193	Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease. *PLoS ONE*, **2020**, 15, e0229710	3.7	5
192	Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease. *Pharmacotherapy*, **2020**, 40, 525-534	5.8	5
191	Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease. *Pharmacotherapy*, **2020**, 40, 535-543	5.8	8
190	Tricuspid regurgitation velocity and other biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the United States: The PUSH study. *American Journal of Hematology*, **2020**, 95, 766-774	7.1	7
189	Prevalence of iron deficiency in 62,685 women of seven race/ethnicity groups: The HEIRS Study. *PLoS ONE*, **2020**, 15, e0232125	3.7	5
188	Alkaline Phosphatase Is Associated with Red Cell Alloimmunization in the Pulmonary Hypertension and Hypoxic Response (PUSH) Sickle Cell Disease Cohort. *Blood*, **2020**, 136, 20-20	2.2	
187	Downregulated KLF2 in PV and ET May Induce Prothrombotic Gene Expression. *Blood*, **2020**, 136, 13-14	2.2	

186	Cancer Incidence and Chemotherapy Tolerance in Patients with Sickle Cell Disease. *Blood*, **2020**, 136, 24-25	2.2	
185	Circulating Extracellular Vesicle Tissue Factor Activity in Chuvash Erythrocytosis. *Blood*, **2020**, 136, 36-36	2.2	
184	Effects of Hydroxyurea and Renin-Angiotensin Blockade on Kidney Function in Sickle Cell Disease. *Blood*, **2020**, 136, 21-22	2.2	
183	Mass-Spectrometry Analysis of Urinary Biomarkers of Endothelial Injury in Sickle Cell Anemia Patients. *Blood*, **2020**, 136, 28-29	2.2	
182	Exercise Induced Changes of Vital Signs in Adults with Sickle Cell Disease. *Blood*, **2020**, 136, 59-60	2.2	
181	Hydroxyurea Use and Outcomes of Pregnancy in Sickle Cell Disease. *Blood*, **2020**, 136, 33-33	2.2	0
180	Predictors of Maternal Morbidity Among Participants Enrolled in the Sickle Cell Disease Implementation Consortium Registry. *Blood*, **2020**, 136, 3-3	2.2	
179	Use of Multiple Urinary Biomarkers for Early Detection of Chronic Kidney Disease in Sickle Cell Anemia Patients. *Blood*, **2020**, 136, 30-30	2.2	0
178	Outcomes in Vaso-Occlusive Crisis Treatment in the Emergency Department Vs. Acute Care Observation Center. *Blood*, **2020**, 136, 22-23	2.2	
177	Lower Apache II Score and Exchange Transfusions Predict Better Outcomes in the Intensive Care Unit for Patients with Sickle Cell Disease. *Blood*, **2020**, 136, 18-19	2.2	
176	Genetic Association of Clinical Complications for Genes Differentially Expressed in Reticulocytes of Sickle Cell Anemia. *Blood*, **2020**, 136, 13-13	2.2	
175	Correction of Point-of-Care International Normalized Ratio (INR) Values in Patients with Sickle Cell Disease. *Blood*, **2020**, 136, 34-35	2.2	
174	Sex Based Differences in Sickle Cell Disease. *Blood*, **2020**, 136, 37-37	2.2	
173	Higher Hemoglobin Levels Achieved with Voxelotor Are Associated with Lower Vaso-occlusive Crisis Incidence: 72-Week Analysis from the HOPE Study. *Blood*, **2020**, 136, 31-32	2.2	7
172	Phlebotomy-Induced Iron Deficiency Increases the Expression of Prothrombotic Genes. *Blood*, **2020**, 136, 11-12	2.2	3
171	Genome Wide Association Analysis of Iron Overload in the Trans-Omics for Precision Medicine (TOPMed) Sickle Cell Disease Cohorts. *Blood*, **2020**, 136, 52-52	2.2	1
170	Prevalence of Sickle Cell Trait and Rare Hemoglobin Variants in the Metropolitan Washington DC Area. *Journal of Hematology (Brossard, Quebec)*, **2020**, 9, 93-95	0.8	2
169	Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study. *JMIR Research Protocols*, **2020**, 9, e16319	2	6

168	S100B has pleiotropic effects on vaso-occlusive manifestations in sickle cell disease. *American Journal of Hematology*, **2020**, 95, E62-E65	7.1	1
167	The impact of delayed treatment of uncomplicated P. falciparum malaria on progression to severe malaria: A systematic review and a pooled multicentre individual-patient meta-analysis. *PLoS Medicine*, **2020**, 17, e1003359	11.6	16
166	Serum albumin is independently associated with higher mortality in adult sickle cell patients: Results of three independent cohorts. *PLoS ONE*, **2020**, 15, e0237543	3.7	0
165	Chronic opioid use can be reduced or discontinued after haematopoietic stem cell transplantation for sickle cell disease. *British Journal of Haematology*, **2020**, 191, e70-e72	4.5	1
164	The CYB5R3 and G6PD A alleles modify severity of anemia in malaria and sickle cell disease. *American Journal of Hematology*, **2020**, 95, 1269-1279	7.1	7
163	Repurposing pyridoxamine for therapeutic intervention of intravascular cell-cell interactions in mouse models of sickle cell disease. *Haematologica*, **2020**, 105, 2407-2419	6.6	1
162	Influence of single parenthood on cardiopulmonary function in pediatric patients with sickle cell anemia. *Blood Advances*, **2020**, 4, 3311-3314	7.8	
161	COVID-19 infection in patients with sickle cell disease. *British Journal of Haematology*, **2020**, 189, 851-852	4.5	66
160	Low hemoglobin increases risk for cerebrovascular disease, kidney disease, pulmonary vasculopathy, and mortality in sickle cell disease: A systematic literature review and meta-analysis. *PLoS ONE*, **2020**, 15, e0229959	3.7	13
159	Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease **2020**, 15, e0229710		
158	Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease **2020**, 15, e0229710		
157	Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease **2020**, 15, e0229710		
156	Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease **2020**, 15, e0229710		
155	Serum albumin is independently associated with higher mortality in adult sickle cell patients: Results of three independent cohorts **2020**, 15, e0237543		
154	Serum albumin is independently associated with higher mortality in adult sickle cell patients: Results of three independent cohorts **2020**, 15, e0237543		
153	Serum albumin is independently associated with higher mortality in adult sickle cell patients: Results of three independent cohorts **2020**, 15, e0237543		
152	Serum albumin is independently associated with higher mortality in adult sickle cell patients: Results of three independent cohorts **2020**, 15, e0237543		
151	Serum albumin is independently associated with higher mortality in adult sickle cell patients: Results of three independent cohorts **2020**, 15, e0237543		

150	Serum albumin is independently associated with higher mortality in adult sickle cell patients: Results of three independent cohorts **2020**, 15, e0237543		
149	Validation of a composite vascular high-risk profile for adult patients with sickle cell disease. *American Journal of Hematology*, **2019**, 94, E312-E314	7.1	2
148	Design of the patient navigator to Reduce Readmissions (PArTNER) study: A pragmatic clinical effectiveness trial. *Contemporary Clinical Trials Communications*, **2019**, 15, 100420	1.8	5
147	"Maximum tolerated dose" vs "fixed low-dose" hydroxyurea for treatment of adults with sickle cell anemia. *American Journal of Hematology*, **2019**, 94, E112-E115	7.1	5
146	Laparoscopic Sleeve Gastrectomy in Sickle Cell Disease: a Case Series. *Obesity Surgery*, **2019**, 29, 3762-3764	3.7	
145	A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. *New England Journal of Medicine*, **2019**, 381, 509-519	59.2	200
144	Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis. *Haematologica*, **2019**, 104, 653-658	6.6	24
143	Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the U.S. population: a six-year population-based cohort analysis. *British Journal of Haematology*, **2019**, 185, 116-127	4.5	9
142	Kidney ultrasound findings according to kidney function in sickle cell anemia. *American Journal of Hematology*, **2019**, 94, E288-E291	7.1	3
141	Type 2 diabetes in adults with sickle cell disease: can we dive deeper? Response to Skinner et al. *British Journal of Haematology*, **2019**, 186, 782-783	4.5	
140	Thrombomodulin and Endothelial Dysfunction in Sickle Cell Anemia. *Blood*, **2019**, 134, 3558-3558	2.2	1
139	Relationship of Host Genetic Factors with Severe Malaria in Nigerian Children. *Blood*, **2019**, 134, 942-942	2.2	
138	Biomarkers of Cardiopulmonary, Renal, and Liver Dysfunction in an Adult Sickle Cell Disease Cohort. *Blood*, **2019**, 134, 3574-3574	2.2	1
137	Manifestations of Reduced Kidney Function Occur at a Higher Estimated Glomerular Filtration Rate in Sickle Cell Anemia. *Blood*, **2019**, 134, 2268-2268	2.2	0
136	Hypoxia Dependent and Independent Dysregulation of the Transcriptome in Sickle Cell Anemia. *Blood*, **2019**, 134, 2262-2262	2.2	
135	The morbidity and mortality of end stage renal disease in sickle cell disease. *American Journal of Hematology*, **2019**, 94, E138-E141	7.1	4
134	Use of metformin in patients with sickle cell disease. *American Journal of Hematology*, **2019**, 94, E13-E15	7.1	2
133	High inpatient dose of opioid at discharge compared to home dose predicts readmission risk in sickle cell disease. *American Journal of Hematology*, **2019**, 94, E5-E7	7.1	1

132	Haploidentical Peripheral Blood Stem Cell Transplantation Demonstrates Stable Engraftment in Adults with Sickle Cell Disease. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1759-1765	4.7	35
131	Patrolling the endothelium in sickle cell disease. *Blood*, **2018**, 131, 1503-1505	2.2	2
130	Progressive glomerular and tubular damage in sickle cell trait and sickle cell anemia mouse models. *Translational Research*, **2018**, 197, 1-11	11	8
129	Urinary orosomucoid is associated with progressive chronic kidney disease stage in patients with sickle cell anemia. *American Journal of Hematology*, **2018**, 93, E107-E109	7.1	9
128	Red blood cell alloimmunization in sickle cell disease: assessment of transfusion protocols during two time periods. *Transfusion*, **2018**, 58, 1588-1596	2.9	8
127	Erythrocytic ferroportin reduces intracellular iron accumulation, hemolysis, and malaria risk. *Science* , **2018**, 359, 1520-1523	33.3	64
126	A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. *New England Journal of Medicine*, **2018**, 379, 226-235	59.2	212
125	Hemolysis and hemolysis-related complications in females vs. males with sickle cell disease. *American Journal of Hematology*, **2018**, 93, E376-E380	7.1	11
124	Regulatory Genetic Variation at the S100B Gene Associates with Vaso-Occlusive Manifestations in Sickle Cell Disease. *Blood*, **2018**, 132, 1063-1063	2.2	1
123	Low Hemoglobin Increases Risk for Stroke, Kidney Disease, Elevated Estimated Pulmonary Artery Systolic Pressure, and Premature Death in Sickle Cell Disease: A Systematic Literature Review and Meta-Analysis. *Blood*, **2018**, 132, 12-12	2.2	1
122	Upregulation of Tissue Factor May Contribute to Thrombosis in Polycythemia Vera and Essential Thrombocythemia. *Blood*, **2018**, 132, 2513-2513	2.2	1
121	Type 2 Diabetes Mellitus in Patients with Sickle Cell Disease: A Population-Based Longitudinal Analysis of Three Cohorts. *Blood*, **2018**, 132, 4817-4817	2.2	1
120	Consistent Compliance with Hydroxyurea and Hematology Measures during L-Glutamine Therapy for Sickle Cell Anemia. *Blood*, **2018**, 132, 3657-3657	2.2	
119	Role of Automated Red Cell Exchange in Acute and Chronic Complications of Sickle Cell Disease. *Blood*, **2018**, 132, 3674-3674	2.2	
118	Tibetan Enriched PKLR Variant Is Beneficial to High Altitude Adaption By Improving Oxygen Delivery. *Blood*, **2018**, 132, 1027-1027	2.2	1
117	Clinical, Laboratory, and Genetic Risk Factors for Thrombosis in Sickle Cell Disease. *Blood*, **2018**, 132, 9-9	2.2	
116	Cancer Incidence in Sickle Cell Disease:an Institutional Experience. *Blood*, **2018**, 132, 1087-1087	2.2	
115	Program expansion of a day hospital dedicated to manage sickle cell pain. *American Journal of Hematology*, **2018**, 93, E20-E21	7.1	5

114	Identification of ceruloplasmin as a biomarker of chronic kidney disease in urine of sickle cell disease patients by proteomic analysis. *American Journal of Hematology*, **2018**, 93, E45-E47	7.1	10
113	Erythropoiesis-stimulating agents in sickle cell anaemia. *British Journal of Haematology*, **2018**, 182, 602-605	4.5	5
112	Characterization of opioid use in sickle cell disease. *Pharmacoepidemiology and Drug Safety*, **2018**, 27, 479-486	2.6	25
111	Sickle Cell Disease Clinical Trials and Phenotypes. *Journal of Tropical Diseases*, **2018**, 6, 259	0	0
110	White Paper: Pathways to Progress in Newborn Screening for Sickle Cell Disease in Sub-Saharan Africa. *Journal of Tropical Diseases*, **2018**, 6, 260	0	9
109	The sickle cell disease implementation consortium: Translating evidence-based guidelines into practice for sickle cell disease. *American Journal of Hematology*, **2018**, 93, E391-E395	7.1	27
108	Risk factors for vitamin D deficiency in sickle cell disease. *British Journal of Haematology*, **2018**, 181, 828-835	4.5	11
107	Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year population-based cohort study. *British Journal of Haematology*, **2018**, 182, 259-270	4.5	12
106	Biomarker signatures of sickle cell disease severity. *Blood Cells, Molecules, and Diseases*, **2018**, 72, 1-9	2.1	13
105	Fixed Low-Dose Hydroxyurea for the Treatment of Adults with Sickle Cell Anemia in Nigeria. *American Journal of Hematology*, **2018**, 93, E193	7.1	7
104	Prospective study of thrombosis and thrombospondin-1 expression in Chuvash polycythemia. *Haematologica*, **2017**, 102, e166-e169	6.6	10
103	Reply to Ruan X et al: "A comment on pattern of opioid use in sickle cell disease". *American Journal of Hematology*, **2017**, 92, E43	7.1	1
102	Gain-of-function EGLN1 prolyl hydroxylase (PHD2 D4E:C127S) in combination with EPAS1 (HIF-2□) polymorphism lowers hemoglobin concentration in Tibetan highlanders. *Journal of Molecular Medicine*, **2017**, 95, 665-670	5.5	38
101	Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. *New England Journal of Medicine*, **2017**, 376, 429-439	59.2	381
100	Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial. *American Journal of Hematology*, **2017**, 92, E520-E528	7.1	23
99	Association of circulating transcriptomic profiles with mortality in sickle cell disease. *Blood*, **2017**, 129, 3009-3016	2.2	14
98	APOL1, □thalassemia, and BCL11A variants as a genetic risk profile for progression of chronic kidney disease in sickle cell anemia. *Haematologica*, **2017**, 102, e1-e6	6.6	28
97	ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease. *Haematologica*, **2017**, 102, 246-259	6.6	20

96	Ethnic and genetic factors of iron status in women of reproductive age. *American Journal of Clinical Nutrition*, **2017**, 106, 1594S-1599S	7	15
95	Increased vancomycin dosing requirements in sickle cell disease due to hyperfiltration-dependent and independent pathways. *Haematologica*, **2017**, 102, e282-e284	6.6	1
94	Associations of ⊟thalassemia and BCL11A with stroke in Nigerian, United States, and United Kingdom sickle cell anemia cohorts. *Blood Advances*, **2017**, 1, 693-698	7.8	8
93	Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease. *Blood Advances*, **2017**, 1, 1645-1649	7.8	28
92	Low Fixed Dose Hydroxyurea for the Treatment of Adults with Sickle Cell Disease in Nigeria. *Blood*, **2017**, 130, 981-981	2.2	3
91	Quantitative Proteomics Identify Urinary Hgfl Protein As a Potential Marker for the Development of Chronic Kidney Disease in Sickle Cell Disease Patients. *Blood*, **2017**, 130, 967-967	2.2	
90	Hypoxic Response-Dependent Genetic Regulation Revealed By Allele-Specific Expression in Reticulocytes of Chuvash Polycythemia. *Blood*, **2017**, 130, 926-926	2.2	
89	A genetic variation associated with plasma erythropoietin and a non-coding transcript of PRKAR1A in sickle cell disease. *Human Molecular Genetics*, **2016**, 25, 4601-4609	5.6	3
88	Impact of a Clinical Pharmacy Service on the Management of Patients in a Sickle Cell Disease Outpatient Center. *Pharmacotherapy*, **2016**, 36, 1166-1172	5.8	6
87	Kidney Disease among Patients with Sickle Cell Disease, Hemoglobin SS and SC. *Clinical Journal of the American Society of Nephrology: CJASN*, **2016**, 11, 207-15	6.9	54
86	SUSTAIN: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises. *Blood*, **2016**, 128, 1-1	2.2	4
85	Urinary Ceruloplasmin Concentration Predicts Development of Kidney Disease in Sickle Cell Disease Patients. *Blood*, **2016**, 128, 4865-4865	2.2	1
84	Hospitalization for Acute Pain in Sickle Cell Disease: Changes in Clinical Parameters and Factors Predicting Hospital Discharge and Re-Admission. *Blood*, **2016**, 128, 3662-3662	2.2	
83	Genome-Wide Analysis Identifies IL-18 and FUCA2 as Novel Genes Associated with Diastolic Function in African Americans with Sickle Cell Disease. *PLoS ONE*, **2016**, 11, e0163013	3.7	8
82	Utility of the revised cardiac risk index for predicting postsurgical morbidity in Hb SC and Hb S⊟-thalassemia sickle cell disease. *American Journal of Hematology*, **2016**, 91, E316-7	7.1	1
81	Preventing delayed hemolytic transfusion reactions in sickle cell disease. *Transfusion*, **2016**, 56, 2899-2900	2.9	7
80	Pathophysiology and treatment of pulmonary hypertension in sickle cell disease. *Blood*, **2016**, 127, 820-8	2.2	84
79	Patterns of opioid use in sickle cell disease. *American Journal of Hematology*, **2016**, 91, 1102-1106	7.1	18

78	Iron, inflammation, and early death in adults with sickle cell disease. *Circulation Research*, **2015**, 116, 298-306	13.7	48
77	Complications in children and adolescents with Chuvash polycythemia. *Blood*, **2015**, 125, 414-5	2.2	10
76	Genetic variants and cell-free hemoglobin processing in sickle cell nephropathy. *Haematologica*, **2015**, 100, 1275-84	6.6	44
75	Platelets decline during Vaso-occlusive crisis as a predictor of acute chest syndrome in sickle cell disease. *American Journal of Hematology*, **2015**, 90, E228-9	7.1	7
74	Metabolic aspects of high-altitude adaptation in Tibetans. *Experimental Physiology*, **2015**, 100, 1247-55	2.4	29
73	Blood transfusion and 30-day readmission rate in adult patients hospitalized with sickle cell disease crisis. *Transfusion*, **2015**, 55, 2331-8	2.9	15
72	Genetic polymorphism of APOB is associated with diabetes mellitus in sickle cell disease. *Human Genetics*, **2015**, 134, 895-904	6.3	14
71	Chronic Opioid Use Pattern in Adult Patients with Sickle Cell Disease. *Blood*, **2015**, 126, 3400-3400	2.2	3
70	Utility of the Revised Cardiac Index Score for Predicting Post-Surgical Outcome in Hb SC or SBeta+ -Thalassemia Sickle Cell Disease. *Blood*, **2015**, 126, 3413-3413	2.2	
69	Association of FOXO3A Polymorphisms with Hematocrit, LDH and Longevity in Patients with Sickle Cell Anemia from CSSCD, Walk-Phasst, and PUSH Clinical Trials. *Blood*, **2015**, 126, 2176-2176	2.2	
68	Impact of a Dedicated Sickle Cell Acute Care Observation Unit on Rate of Hospital Admission for Acute Pain Crisis. *Blood*, **2015**, 126, 4584-4584	2.2	
67	The Effect of IV Iron Therapy on HIF Pathway and HIF Regulated Genes in Elderly Patients with Unexplained Anemia. *Blood*, **2015**, 126, 4533-4533	2.2	
66	Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia. *British Journal of Haematology*, **2014**, 164, 729-39	4.5	75
65	Differences in the clinical and genotypic presentation of sickle cell disease around the world. *Paediatric Respiratory Reviews*, **2014**, 15, 4-12	4.8	59
64	Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2014**, 69, 725-35	6.4	188
63	An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 189, 727-40	10.2	154
62	Iron deficiency modifies gene expression variation induced by augmented hypoxia sensing. *Blood Cells, Molecules, and Diseases*, **2014**, 52, 35-45	2.1	18
61	ARTS: automated randomization of multiple traits for study design. *Bioinformatics*, **2014**, 30, 1637-9	7.2	2

60	Abnormal pulmonary function and associated risk factors in children and adolescents with sickle cell anemia. *Journal of Pediatric Hematology/Oncology*, **2014**, 36, 185-9	1.2	35
59	Hypoxic response contributes to altered gene expression and precapillary pulmonary hypertension in patients with sickle cell disease. *Circulation*, **2014**, 129, 1650-8	16.7	27
58	Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom. *PLoS ONE*, **2014**, 9, e99489	3.7	82
57	Genetic determinants of haemolysis in sickle cell anaemia. *British Journal of Haematology*, **2013**, 161, 270-8	4.5	35
56	The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. *Haematologica*, **2013**, 98, 464-72	6.6	135
55	Reduced sensitivity of the ferroportin Q248H mutant to physiological concentrations of hepcidin. *Haematologica*, **2013**, 98, 455-63	6.6	18
54	Neutrophil Akt2 Plays a Critical Role In Heterotypic Neutrophil-Platelet Interactions During Vascular Inflammation. *Blood*, **2013**, 122, 321-321	2.2	1
53	Hemoglobinuria Is a Risk Factor For Kidney Disease Progression In Sickle Cell Anemia. *Blood*, **2013**, 122, 996-996	2.2	
52	Genetic Association Of a MAPK8 Expression Quantitative Trait Locus With Pre-Capillary Pulmonary Hypertension In Sickle Cell Disease. *Blood*, **2013**, 122, 991-991	2.2	
51	Meta-analysis of 2040 sickle cell anemia patients: BCL11A and HBS1L-MYB are the major modifiers of HbF in African Americans. *Blood*, **2012**, 120, 1961-2	2.2	64
50	Dietary iron intake and serum ferritin concentration in 213 patients homozygous for the HFEC282Y hemochromatosis mutation. *Canadian Journal of Gastroenterology & Hepatology*, **2012**, 26, 345-9		17
49	Role of Ethnicity in Clinical Outcomes of Patients with Ph-Negative Myeloproliferative Neoplasms. *Blood*, **2012**, 120, 2076-2076	2.2	1
48	The Hypoxic Response and Altered Gene Expression in Patients with Sickle Cell Disease. *Blood*, **2012**, 120, 3245-3245	2.2	
47	Pain Medication: Time to First Dose in Sickle Cell Acute Care in Two Settings of a Large Urban Hospital. *Blood*, **2012**, 120, 4693-4693	2.2	
46	Renal Disease in Sickle Cell: Clinically Varied and Associated with Increased Mortality. *Blood*, **2012**, 120, 90-90	2.2	2
45	Clinical and Laboratory Predictors for Renal Damage in Sickle Cell Disease. *Blood*, **2012**, 120, 3252-3252	2.2	
44	Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. *Blood*, **2011**, 118, 855-64	2.2	179
43	Chuvash polycythemia VHLR200W mutation is associated with down-regulation of hepcidin expression. *Blood*, **2011**, 118, 5278-82	2.2	31

42	Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia. *Haematologica*, **2011**, 96, 33-40	6.6	60
41	Distinct clinical and immunologic profiles in severe malarial anemia and cerebral malaria in Zambia. *Journal of Infectious Diseases*, **2011**, 203, 211-9	7	43
40	Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom. *Circulation*, **2011**, 124, 1452-60	16.7	97
39	Association of G6PD with lower haemoglobin concentration but not increased haemolysis in patients with sickle cell anaemia. *British Journal of Haematology*, **2010**, 150, 218-25	4.5	25
38	Prospective echocardiography assessment of pulmonary hypertension and its potential etiologies in children with sickle cell disease. *American Journal of Cardiology*, **2009**, 104, 713-20	3	49
37	Prospective evaluation of haemoglobin oxygen saturation at rest and after exercise in paediatric sickle cell disease patients. *British Journal of Haematology*, **2009**, 147, 352-9	4.5	53
36	Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation. *Haematologica*, **2009**, 94, 340-7	6.6	142
35	Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease. *Blood*, **2009**, 114, 4639-44	2.2	56
34	Ferroportin Q248h, dietary iron, and serum ferritin in community African-Americans with low to high alcohol consumption. *Alcoholism: Clinical and Experimental Research*, **2008**, 32, 1947-53	3.7	5
33	Severe Vaso-Occlusive Episodes Associated with Use of Systemic Corticosteroids in Patients with Sickle Cell Disease. *Journal of the National Medical Association*, **2008**, 100, 948-951	2.3	55
32	Serum ferritin concentrations and body iron stores in a multicenter, multiethnic primary-care population. *American Journal of Hematology*, **2008**, 83, 618-26	7.1	30
31	Association of ferroportin Q248H polymorphism with elevated levels of serum ferritin in African Americans in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. *Blood Cells, Molecules, and Diseases*, **2007**, 38, 247-52	2.1	41
30	Circumstances of death in adult sickle cell disease patients. *American Journal of Hematology*, **2006**, 81, 858-63	7.1	196
29	Vascular complications in Chuvash polycythemia. *Seminars in Thrombosis and Hemostasis*, **2006**, 32, 289-94	3.3	42
28	Is a little hypoxia good for you?. *Blood*, **2006**, 107, 417-418	2.2	
27	Dietary Iron, Alcohol Consumption and Serum Ferritin Concentrations in African Americans.. *Blood*, **2006**, 108, 1551-1551	2.2	
26	The association of serum ferritin and transferrin receptor concentrations with mortality in women with human immunodeficiency virus infection. *Haematologica*, **2006**, 91, 739-43	6.6	28
25	Effect of ferroportin Q248H polymorphism on iron status in African children. *American Journal of Clinical Nutrition*, **2005**, 82, 1102-6	7	35

24	Prevalence of Pulmonary Hypertension and Renal Dysfunction by Systemic Blood Pressure Categories in Sickle Cell Disease.. *Blood*, **2005**, 106, 3169-3169	2.2	2
23	Cancer Incidence in Sickle Cell Disease. Howard University, 1996–2004.. *Blood*, **2005**, 106, 3788-3788	2.2	
22	Initial Screening Transferrin Saturation Values, Serum Ferritin Concentrations, and HFE Genotypes in Native Americans and Whites in the Hemochromatosis and Iron Overload Screening (HEIRS) Study.. *Blood*, **2005**, 106, 3712-3712	2.2	
21	Unexplained Serum Ferritin Elevations in Primary Care Patients with Elevated Serum Ferritin Concentrations and High Normal Transferrin Saturations.. *Blood*, **2005**, 106, 3729-3729	2.2	
20	Congenital polycythemias/erythrocytoses. *Haematologica*, **2005**, 90, 109-16	6.6	74
19	Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. *Blood*, **2004**, 103, 3924-32	2.2	205
18	Prevalence of Pulmonary Hypertension (PHTN) in Sickle Cell Disease (SCD) Adolescents with Pulmonary Complications.. *Blood*, **2004**, 104, 3759-3759	2.2	
17	Fluorescence measurements of the labile iron pool of sickle erythrocytes. *Blood*, **2003**, 102, 357-64	2.2	37
16	Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. *Blood Cells, Molecules, and Diseases*, **2003**, 31, 299-304	2.1	160
15	Genetics, diagnosis and treatment of hemochromatosis. *Clinical Advances in Hematology and Oncology*, **2003**, 1, 216-7	0.6	
14	Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. *Nature Genetics*, **2002**, 32, 614-21	36.3	407
13	African iron overload. *Seminars in Hematology*, **2002**, 39, 263-9	4	72
12	Assessment of antimalarial effect of ICL670A on in vitro cultures of Plasmodium falciparum. *British Journal of Haematology*, **2001**, 115, 918-23	4.5	10
11	Predicting mortality in patients with malarial acute renal failure. *Nephrology*, **2000**, 5, 109-113	2.2	1
10	Severe anaemia in Zambian children with Plasmodium falciparum malaria. *Tropical Medicine and International Health*, **2000**, 5, 9-16	2.3	56
9	Markers of inflammation in children with severe malarial anaemia. *Tropical Medicine and International Health*, **2000**, 5, 256-262	2.3	38
8	Transferrin Polymorphism Influences Iron Status in Blacks. *Clinical Chemistry*, **2000**, 46, 1535-1539	5.5	37
7	Iron overload in African Americans **2000**, 475-484		6

6	Non-transferrin-bound iron and hepatic dysfunction in African dietary iron overload. *Journal of Gastroenterology and Hepatology (Australia)*, **1999**, 14, 126-32	4	25
5	The eosinophilic response and haematological recovery after treatment for Plasmodium falciparum malaria. *Tropical Medicine and International Health*, **1999**, 4, 471-5	2.3	16
4	African iron overload and hepatocellular carcinoma (HA-7-0-080). *European Journal of Haematology*, **1998**, 60, 28-34	3.8	40
3	Dietary iron overload as a risk factor for hepatocellular carcinoma in Black Africans. *Hepatology*, **1998**, 27, 1563-6	11.2	138
2	Distribution of Transferrin Saturations in the African-American Population. *Blood*, **1998**, 91, 2175-2179	2.2	32
1	Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study (Preprint)		1